Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents
about
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteriaColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyActivity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbationsClinical significance of microbial infection and adaptation in cystic fibrosis.The use of intravenous colistin among children in the United States: results from a multicenter, case seriesSystematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Aminoglycoside resistance in Pseudomonas aeruginosa.Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.Targeted Antibiotic Prophylaxis for Lung Transplantation in Cystic Fibrosis Patients Colonised with Pseudomonas aeruginosa Using Multiple Combination Bactericidal Testing.Survey of acute renal failure in patients with cystic fibrosis in the UK.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia.Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic FibrosisGenetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium.Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.Update on the treatment of Pseudomonas aeruginosa pneumonia.Optimizing treatment policies and improving care: impact on outcome in patients with cystic fibrosis.Colistin: an update on the antibiotic of the 21st century.Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature.Liposomal antibiotics for the treatment of infectious diseases.Chronic pulmonary pseudomonal infection in patients with cystic fibrosis: A model for early phase symbiotic evolution.Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings.Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.Aminoglycoside-induced nephrotoxicity in children.Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.K1K8: an Hp1404-derived antibacterial peptide.Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosisReduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.Comparative Molecular docking analysis of DNA Gyrase subunit A in Pseudomonas aeruginosaPAO1.
P2860
Q24794555-65AF07BE-D2B1-457F-9807-A9818015EA79Q27014993-7A32CD4A-E407-4AF2-986C-EB719CA4134AQ33938255-93004509-8C64-4F4D-B9BC-7BA5C5299790Q34297656-19FA68C6-6A9A-4E71-9476-699D705741F7Q34437958-D163872E-3F66-480E-A5E1-EF175E409CFAQ34491552-9806351B-3AE9-4D67-A215-23002366DCF7Q35592264-65A640EC-53F9-4A06-A12B-7B36440D8B51Q35878860-406BE8C1-3F56-43A3-B06C-2F3ECC0ED230Q36021296-1716C180-3463-4FD5-A248-08E127E0F1B1Q36059706-8582EF94-64E7-4C8F-8D6C-184BA0CBF445Q36118861-0C1EFE6A-C1FD-4F77-A899-6A3FC1376239Q36225726-66524DA7-5AA1-4822-A22D-C08B17DAC26CQ36337074-A8CC062A-85D8-40E1-A117-C58AFA9A9BE8Q36364034-24757E97-C402-4297-B6FB-AA484068A4F0Q36646981-2489A154-C672-4C8C-9CC2-B58C9B3A32CDQ36658777-A2260174-429A-48A6-B9B5-7F393372E1C5Q36677316-8D6C08B9-F3DB-40AC-8F59-7F5D4F9A44ACQ36980425-B253149F-E229-4AE4-8614-0B10C2FDC650Q37110307-C146A019-4D75-4059-AEBD-46E09B340BF9Q37204246-5C4153BC-AFE6-4E48-B6CB-9256C6E8D67FQ37333080-E5B6C40E-AF82-4852-904A-DBF2D693CC84Q37516904-93D3B39F-4C2A-4007-BB19-76516FEC42D2Q37609433-8A076D20-9569-4403-8FCA-64B416C3024EQ38048852-B83D466E-4632-49C2-BDE4-FD694C4F668BQ38123731-32E68AE8-4568-4993-AED8-A9A2D3F89230Q38124144-2C5632CF-3F4A-4D9B-B356-C1CF2DC83751Q38207078-2D9310B9-9B8C-496C-A204-BDAE7BE593F0Q38211644-6B3D40D9-D2FF-4614-99D2-04BDC00B387DQ38268531-D2508BF6-6CCF-4FCA-8743-1EF75044D3DEQ38599969-2B8E133D-420C-4129-9C7F-49FA728611B7Q38795059-97923CAB-3712-4527-88EA-C8682FEFCDF1Q40559360-1EAC2676-409C-42BA-AAE7-0B18A862B3ABQ40764253-51B90291-4F4C-48AB-8FBB-026B9E9355D0Q40953294-7154DBC4-525D-4452-B52F-DC86CC4C7C2CQ41063056-EB407690-ECAE-415C-87B1-BBB7B2DE93ACQ41913112-BADD214F-0F21-4CCE-81B2-53343FF3FC5DQ42612276-9C98F6AE-58E1-4DB9-80A9-3ABBB681D4E2Q42751901-2AEECEA3-51A5-498B-9BDE-E0AE73BBF7AAQ42927531-0D9DF970-0965-40A9-906C-5D3B49EE2B7CQ43239971-E35313E8-4C17-4AE5-9192-03B77F122B2C
P2860
Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Survey of resistance of Pseudo ...... rescribed antimicrobial agents
@ast
Survey of resistance of Pseudo ...... rescribed antimicrobial agents
@en
type
label
Survey of resistance of Pseudo ...... rescribed antimicrobial agents
@ast
Survey of resistance of Pseudo ...... rescribed antimicrobial agents
@en
prefLabel
Survey of resistance of Pseudo ...... rescribed antimicrobial agents
@ast
Survey of resistance of Pseudo ...... rescribed antimicrobial agents
@en
P2093
P2860
P356
P1433
P1476
Survey of resistance of Pseudo ...... rescribed antimicrobial agents
@en
P2093
P2860
P304
P356
10.1136/THORAX.58.9.794
P407
P577
2003-09-01T00:00:00Z